In a cover story for BusinessWeek, Carey wrote a thought-provoking, carefully documented piece looking at the question of whether the benefits of statin drugs may be overstated except in the case of high-risk heart patients. The story looked at the statistical methods used in research on statins, including the little-known but useful statistic called the “number needed to treat,” or NNT. Carey also discussed the design of clinical trials aimed at proving the benefit of heart drugs and the underlying biochemistry of statins. Guy Gugliotta, a freelance science writer, called the story “informative, brightly written and a most welcome destruction of the conventional wisdom.” Pete Spotts of The Christian Science Monitor said it was a “clear public service in highlighting the shortcomings of drug trials for cholesterol drugs.”